주요 내용으로 건너 뛰기

Evaluating the IRA’s Impact on Medicare Part B Biosimilar Reimbursement

One less-publicized provision of the Inflation Reduction Act (IRA) enacts a five-year boost in Medicare Part B reimbursement for biosimilar drugs (also known as follow-on biologics or subsequent entry biologics). The biosimilar reimbursement enhancement is meant to overcome financial disincentives to adoption.

Complete the form to download a free copy of the IRA Biosimilars Outlook 2024 Report

The research delves into the IRA’s “small but measurable” impact and offers insights in several key areas, such as:

  • The relationship between awareness of IRA enhanced Medicare part B reimbursement and utilization of biosimilars at oncology treatment sites
  • Facility characteristics associated with level of biosimilar utilization
  • Relationship between eligibility for the IRA biosimilar reimbursement boost and uptake
  • Drivers of and impediments to biosimilar uptake
  • Trends in oncology biosimilar uptake and market share

If you’re interested in discussing this topic or other U.S. access trends with our experts, you can contact them directly.

Authors

Caitlin Verrilli, MBA, Director, US Access Strategy
caitlin.verrilli@certara.com

Max Vargas, PhD, MBA, Vice President, US Access Strategy
maximilian.vargas@certara.com

Matias Junghahn, Senior Analyst
matias.junghahn@certara.com

Powered by Translations.com GlobalLink Web Software